These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 32360576)

  • 1. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
    Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
    Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA.
    Woodward EA; Wang E; Wallis C; Sharma R; Tie AWJ; Murthy N; Blancafort P
    Methods Mol Biol; 2024; 2842():267-287. PubMed ID: 39012601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.
    Boucher P; Cui X; Curiel DT
    J Control Release; 2020 Nov; 327():788-800. PubMed ID: 32891680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases.
    Yu W; Wu Z
    Adv Drug Deliv Rev; 2021 Jan; 168():181-195. PubMed ID: 32603815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
    Cheng X; Fan S; Wen C; Du X
    Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment based stimuli-responsive CRISPR/Cas delivery systems: A viable platform for interventional approaches.
    Tang N; Ning Q; Wang Z; Tao Y; Zhao X; Tang S
    Colloids Surf B Biointerfaces; 2022 Feb; 210():112257. PubMed ID: 34894597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational designs of in vivo CRISPR-Cas delivery systems.
    Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
    Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
    Wan T; Ping Y
    Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress and challenges towards CRISPR/Cas clinical translation.
    Rosenblum D; Gutkin A; Dammes N; Peer D
    Adv Drug Deliv Rev; 2020; 154-155():176-186. PubMed ID: 32659256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
    Shalaby K; Aouida M; El-Agnaf O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy.
    Yi K; Kong H; Lao YH; Li D; Mintz RL; Fang T; Chen G; Tao Y; Li M; Ding J
    Adv Mater; 2024 Mar; 36(13):e2300665. PubMed ID: 37437039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral Delivery of Compact CRISPR-Cas12f for Gene Editing Applications.
    Sharrar A; Meacham Z; Staples-Ager J; Arake de Tacca L; Rabuka D; Collingwood T; Schelle M
    CRISPR J; 2024 Jun; 7(3):150-155. PubMed ID: 38695159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas gene editing and delivery systems for cancer therapy.
    Li Y; Zhou S; Wu Q; Gong C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1938. PubMed ID: 38456346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.